All Sauce from Weekly Sauce:

The use of nicotine pouches nearly doubled among U.S. high school students between 2023 and 2024, a new study says. These pouches, inserted between the gum and lip, provide teenagers an opportunity to use nicotine in a discreet, easily concealed way, researchers said. About 5.4% of teens said they used nicotine pouches in 2024, compared…  read on >  read on >

Conversion therapy might harm a young person’s long-term heart health, a new study says. Young adults assigned male at birth were nearly three times as likely to be diagnosed with high blood pressure if they’d been exposed to conversion therapy, a discredited practice that attempts to alter a person’s sexual orientation or gender identity, researchers…  read on >  read on >

Stress can make it even worse for people to deal with chronic obstructive pulmonary disease, or COPD, a new study says. High levels of perceived stress are associated with a quadrupled risk of moderate or severe COPD flare-ups (excerbations), researchers reported recently in the Journal of the COPD Foundation. “There is increased evidence that psychosocial…  read on >  read on >

The shingles vaccine has benefits that stretch beyond protecting older adults from the painful skin condition, a new study says. Folks who get the shingles jab have a 23% lower risk of health problems like stroke, heart failure and heart disease, researchers reported May 6 in the European Heart Journal. This protective effect lasts for…  read on >  read on >

The head of the U.S. Food and Drug Administration (FDA) reiterated Tuesday that the agency is applying a more skeptical approach to this year’s round of COVID-19 vaccine boosters. Companies applying for approval of COVID boosters are being encouraged to use “gold standard science,” including full-fledged clinical trials involving healthy people, FDA Commissioner Dr. Marty…  read on >  read on >

Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment, researchers report. Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health. The antibody treatment also reduced the risk…  read on >  read on >